NHP Publishes Guideline for use of Crizanlizumab

Written By U'mau Otuokon

Following NICE recommendation of Crizanlizumab as a treatment option for preventing recurrent crises (vaso-occlusive crises, VOCs) in people aged 16 or over with sickle cell disease (SCD), the NHP has published this guideline in line with NICE Managed Access Agreement (MAA)- January 2022

U'mau Otuokon
Previous

NHP Annual Report 2020/2021
Next

New guidance for clinicians on COVID-19 in patients with haemoglobinopathies and inherited rare anaemias.